Uttarakhand News Today

Dry Eye Disease Clinical Trials and Pipeline Analysis 2023: FDA, EMA and PDMA Approval, Therapies, Latest updates and Companies by DelveInsight | Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharma

 Breaking News
  • No posts were found

Dry Eye Disease Clinical Trials and Pipeline Analysis 2023: FDA, EMA and PDMA Approval, Therapies, Latest updates and Companies by DelveInsight | Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharma

April 06
14:48 2023
Dry Eye Disease Clinical Trials and Pipeline Analysis 2023: FDA, EMA and PDMA Approval, Therapies, Latest updates and Companies by DelveInsight | Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharma
Dry Eye Disease Pipeline
As per DelveInsight’s assessment, globally, Dry Eye Disease pipeline constitutes 50+ key companies continuously working towards developing 50+ Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

(Albany, USA) DelveInsight’s, “Dry Eye Disease Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

To know more in detail about the Dry Eye Disease treatment drugs, click here @ Dry Eye Disease drugs in different phases

 

Dry Eye Disease Overview

Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality.

 

Key takeaways from the Dry Eye Disease Pipeline Insight Report

  • DelveInsight’s Dry Eye Disease pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies.
  • The leading Dry Eye Disease Companies are working such as Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharmaceutical, AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb, TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
  • Promising Dry Eye Disease Pipeline Therapies such as Reproxalap, Timbetasin, Visomitin, and others.
  • The Dry Eye Disease Companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The Dry Eye Disease pipeline therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.

 

To explore more information on the latest breakthroughs in the Dry Eye Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight

 

Recent Breakthroughs of Dry Eye Disease Treatment Landscape

  • In a Phase II b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
  • RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.
  • Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

 

To explore more information on the latest breakthroughs in the Dry Eye Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight

 

Emerging Dry Eye Disease Drugs Profile

  • Reproxalap: Aldeyra Therapeutics

Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

  • Timbetasin: RegeneRx Biopharmaceuticals

RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

  • Visomitin: Mitotech

Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

 

Learn more about the emerging Dry Eye Disease pipeline therapies @ https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight

 

Dry Eye Disease Pipeline Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.

 

Scope of the Dry Eye Disease Pipeline Report

  • Coverage- Global
  • Dry Eye Disease Pipeline Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration
  • Dry Eye Disease Companies– TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
  • Dry Eye Disease Pipeline Therapies- Reproxalap, Timbetasin, Visomitin, and others

 

Learn more about the emerging Dry Eye Disease pipeline therapies @ Dry Eye Disease Clinical Trials Analysis – @ https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight

 

Table of Content

  1. Introduction
  2. Dry Eye Disease Executive Summary
  3. Dry Eye Disease Overview
  4. Dry Eye Disease Pipeline Therapeutics
  5. Dry Eye Disease Pipeline Therapeutic Assessment
  6. Dry Eye Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name: Company Name
  9. Last Stage Products (Phase III)
  10. Timbetasin: RegeneRx Biopharmaceuticals
  11. Mid Stage Products (Phase II)
  12. Drug name: Company name
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Dry Eye Disease Key Companies
  17. Dry Eye Disease Key Products
  18. Dry Eye Disease – Unmet Needs
  19. Dry Eye Disease – Market Drivers and Barriers
  20. Dry Eye Disease – Future Perspectives and Conclusion
  21. Dry Eye Disease Analyst Views
  22. Dry Eye Disease Key Companies
  23. Appendix

 

About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles